Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people

Trials

Rosalind L Smyth²  Paula R Williamson¹  Ruairi Gallagher²  Ian P Sinha² 

[1] Centre for Medical Statistics and Health Evaluation, University of Liverpool, Brownlow Hill, Liverpool, L69 3GS, UK;Institute of Child Health, University of Liverpool, Alder Hey Children’s Hospital, Alder Road, Liverpool, L12 2AP, UK

关键词: Paediatrics;    Children;    Delphi;    Core outcome set;    Asthma;   

Others  :  1095485
DOI  :  10.1186/1745-6215-13-103

 received in 2012-01-22, accepted in 2012-07-02,  发布年份 2012

【 摘 要 】

Background

In clinical trials in childhood asthma, outcomes reflecting short-term disease activity are frequently measured, whilst functional status, quality of life (QoL), and long-term treatment effects are rarely assessed. There is also non-uniformity across studies in the selection and measurement of outcomes within these domains. The development of a core outcome set has the potential to reduce heterogeneity between trials, lead to research that is more likely to have measured relevant outcomes, and enhance the value of evidence synthesis by reducing the risk of outcome reporting bias and ensuring that all trials contribute usable information.

Methods

Paediatricians and specialist nurses, identified through the British Paediatric Respiratory Society, completed a two-round Delphi survey. Separate cohorts of parents of children younger than 18 years, recruited in clinics, participated in each round. Young people with asthma, aged at least 13 years, participated in the first round. Outcomes were identified separately for preschool and school-aged children.

We identified outcomes considered important in routine clinical assessment by clinicians and parents/young people. In round 1, 46 clinicians suggested outcomes they considered important when deciding whether to adjust a child’s asthma therapy regime, and 49 parents/young people were asked, using open questions, how they judged whether their child’s (for young people, their own) asthma therapy was appropriate. Two researchers independently classified responses into appropriate, corresponding outcomes.

In round 2, 43 clinicians and 50 parents scored, from 0–4, the importance of each outcome suggested by at least 10 % of round 1 responders and selected the three most important.

Results

The most important outcomes, when making shared decisions about regular therapies for school-aged and preschool children with asthma, were daytime and nocturnal symptoms, exacerbations, QoL, and mortality. Results from parents and clinicians were generally concordant, but parents placed more emphasis on long-term treatment effects.

Conclusions

We have developed a methodology to identify outcomes of most relevance to clinicians, parents, and young people when evaluating regularly administered therapies for asthma. Daytime and nocturnal symptoms, exacerbations, QoL, and mortality are particularly important outcomes that should be measured and reported in all clinical trials of regular therapies for children with asthma.

【 授权许可】

   
2012 Sinha et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Sinha I, Jones L, Smyth RL, Williamson PR: A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med 2008, 5(4):e96.
• [2]Smith MA, Leeder SR, Jalaludin B, Smith WT: The asthma health outcome indicators study. Aust N Z J Public Health 1996, 20(1):69-75.
• [3]Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al.: An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180(1):59.
• [4]Sinha IP, Williamson PR, Smyth RL: Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity. PLoS One 2009, 4(7):e6276.
• [5]Clarke M: Standardising outcomes in paediatric clinical trials. PLoS Med 2008, 5:4.
• [6]Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L: OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007, 8(1):38. BioMed Central Full Text
• [7]Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al.: Incorporating the patient perspective into outcome assessment in rheumatoid arthritis–progress at OMERACT 7. J Rheumatol 2005, 32(11):2250.
• [8]Williamson P, Altman D, Blazeby J, Clarke M, Gargon E: Driving up the quality and relevance of research through the use of agreed core outcomes. J Health Serv Res Policy 2012, 17:1.
• [9]Sinha IP, Smyth RL, Williamson PR: Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med 2011, 8(1):e1000393.
• [10]Kroegel C, Wirtz H: History of guidelines for the diagnosis and management of asthma: from opinion to control. Drugs 2009, 69(9):1189-1204.
• [11]van den Bemt L, Kooijman S, Linssen V, Lucassen P, Muris J, Slabbers G, Schermer T: How does asthma influence the daily life of children? Results of focus group interviews. Health Qual Life Outcomes 2010, 8(1):5. BioMed Central Full Text
• [12]Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O’Byrne PM: Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004, 23(2):287.
• [13]Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al.: Outcome of asthma and wheezing in the first six years of life: follow-up through adolescence. Am J Respir Crit Care Med 2005, 172:1253-1258.
• [14]Townsend M, Feeny DH, Guyatt GH, Furlong WJ, Seip AE, Dolovich J: Evaluation of the burden of illness for pediatric asthmatic patients and their parents. Ann Allergy 1991, 67(4):403.
• [15]Garattini S, Chalmers I: Patients and the public deserve big changes in evaluation of drugs. Br Med J 2009, 338(3):b1025.
• [16]Griffiths AM, Otley AR, Hyams J, Quiros AR, Grand RJ, Bousvaros A, et al.: A review of activity indices and end points for clinical trials in children with Crohn’s disease. Inflamm Bowel Dis 2005, 11(2):185-196.
• [17]Sridhar AV, McKean MC: Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006. Issue 3. Art. No.: CD004108
• [18]Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ: Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008. Issue 4. Art. No.: CD003534
• [19]Adams NP, Bestall JC, Jones P: Budesonide versus placebo for chronic asthma in children and adults. Cochrane Database Syst Rev 2001. Issue 4. Art. No.: CD003271